Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) EBIT (2019 - 2025)

Benitec Biopharma (BNTC) has disclosed EBIT for 7 consecutive years, with -$17.2 million as the latest value for Q2 2025.

  • Quarterly EBIT fell 209.59% to -$17.2 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$30.3 million through Jun 2025, down 34.77% year-over-year, with the annual reading at -$41.8 million for FY2025, 85.7% down from the prior year.
  • EBIT hit -$17.2 million in Q2 2025 for Benitec Biopharma, down from -$5.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$2.2 million in Q4 2024 to a low of -$17.2 million in Q2 2025.
  • Historically, EBIT has averaged -$5.4 million across 5 years, with a median of -$4.8 million in 2021.
  • Biggest five-year swings in EBIT: soared 68.31% in 2024 and later crashed 209.59% in 2025.
  • Year by year, EBIT stood at -$4.8 million in 2021, then decreased by 16.03% to -$5.6 million in 2022, then decreased by 23.48% to -$6.9 million in 2023, then skyrocketed by 68.31% to -$2.2 million in 2024, then tumbled by 682.51% to -$17.2 million in 2025.
  • Business Quant data shows EBIT for BNTC at -$17.2 million in Q2 2025, -$5.1 million in Q1 2025, and -$2.2 million in Q4 2024.